Encephalopathy after high-dose ifosfamide: A retrospective cohort study and review of the literature

Drug Safety

Volumn 31, Issue 11, 2008, Pages 989-996

  Sweiss, Karen I ^a   Beri, Rakesh ^a   Shord, Stacy S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Encephalopathy, drug induced; Ifosfamide, adverse reactions

Indexed keywords

ALBUMIN; BILIRUBIN; HEMOGLOBIN; IFOSFAMIDE; METHYLENE BLUE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPOALBUMINEMIA; MALE; MEDLINE; OBESITY; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE SARCOMA;

ADULT; ALBUMINS; ANTINEOPLASTIC AGENTS, ALKYLATING; BILIRUBIN; BRAIN DISEASES; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; HEMOGLOBINS; HUMANS; IFOSFAMIDE; MALE; METHYLENE BLUE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA; SEX FACTORS;

EID: 53549115633     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831110-00003     Document Type: Article

References (41)

1. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005; 28 (3): 277-80
2. Miller LJ, Eaton VE. Ifosfamide-induced neurotoxicity: a case report and review of the literature. Ann Pharmacother 1992; 26 (2): 183-7
3. Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004; 15 (4): 347-50
4. DiMaggio JR, Brown R, Baile WF, et al. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73 (5): 1509-14
5. Merimsky O, Reider-Groswasser I, Wigler N, et al. Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 1992; 86 (5): 521-5
6. Curtin JP, Koonings PP, Gutierrez M, et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991; 42 (3): 193-6; discussion 191-2
7. Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003; 15 (7): 435-9
8. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82 (2): 291-4
9. Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006; 40 (2): 299-303
10. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17 (5 Pt 2): 146S-54S
11. Meanwell CA, Kelly KA, Blackledge G. Avoiding ifosfamide/mesna encephalopathy. Lancet 1986; 2 (8503): 406
12. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000; 38 (4): 291-304
13. Chen CS, Jounaidi Y, Waxman DJ. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos 2005; 33 (9): 1261-7
14. Roy P, Tretyakov O, Wright J, et al. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 1999; 27 (11): 1309-18
15. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59 (8): 961-72
16. Goren MP, Wright RK, Pratt CB, et al. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; 2 (8517): 1219-20
17. Wainer IW, Ducharme J, Granvil CP, et al. Ifosfamide stereoselective dichloroethylation and neurotoxicity. Lancet 1994; 343 (8903): 982-3
18. Meanwell CA, Blake AE, Latief TN, et al. Encephalopathy associated with ifosphamide/mesna therapy. Lancet 1985; 1 (8425): 406-7
19. Cantwell BM, Harris AL. Ifosfamide/mesa and encephalopathy. Lancet 1985; 1 (8431): 752
20. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22 (7): 815-9
21. Heim ME, Fiene R, Schick E, et al. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 1981; 100 (1): 113-6
22. Brade WP, Herdrich K, Varini M. Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12 (1): 1-47
23. Lind MJ, Margison JM, Cerny T, et al. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989; 49 (3): 753-7
24. Cerny T, Castiglione M, Brunner K, et al. Ifosfamide by continuous infusion to prevent encephalopathy [letter]. Lancet 1990; 335 (8682): 175
25. Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: report of five cases and review of the literature. Drugs Aging 2007; 24 (11): 967-73
26. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004; 65 (5): 1278-85
27. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001; 40 (1): 41-62
28. Highley MS, Schrijvers D, Van Oosterom AT, et al. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann Oncol 1997; 8 (11): 1139-44
29. Schmidt R, Baumann F, Hanschmann H, et al. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 2001; 26 (3): 193-200
30. Freyer G, Tranchand B, Ligneau B, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000; 50 (4): 315-24
31. Kerbusch T, Mathjt RA, Keizer HJ, et al. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Eur J Clin Pharmacol 2001; 57 (6-7): 467-77
32. Perren TJ, Turner RC, Smith IE. Encephalopathy with rapid infusion ifosfamide/mesna. Lancet 1987; 1 (8529): 390-1
33. Salloum E, Flamant F, Ghosn M, et al. Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 1987; 5 (8): 1303-4
34. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 1990; 17 (2 Suppl. 4): 68-73
35. Ferrero JM, Eftekari P, Largillier R, et al. Treatment of ifosfamide induced encephalopathy with methylene-blue [in French]. Bull Cancer 1995; 82 (7): 598-9
36. Kupfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343 (8900): 763-4
37. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 1995; 332 (18): 1239-40
38. Alonso JL, Nieto Y, Lopez JA, et al. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol 1996; 7 (6): 643-4
39. Demandt M, Wandt H. Successful treatment with methylene blue of ifosfamide-induced central nervous system effects [letter; in German]. Dtsch Med Wochenschr 1996; 121 (17): 575
40. Koschuth A, Spath-Schwalbe PE, Possinger K. Methylene blue in ifosfamide-induced encephalopathy [letter; in German]. Dtsch Med Wochenschr 1996; 121 (39): 1210
41. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology 2003; 65 Suppl. 2: 11-6